Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YOUXZ
ADC Name
HB22.7-SAP
Synonyms
HB22.7 SAP
   Click to Show/Hide
Organization
University of California
Drug Status
Investigative
Indication
In total 1 Indication(s)
Non Hodgkin lymphoma [ICD11:2B33]
Investigative
Antibody Name
Anti-CD22 mAb HB22.7
  Antibody Info 
Antigen Name
B-cell receptor CD22 (CD22)
  Antigen Info 
Payload Name
Saporin
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 10 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 2.67
%
Raji cells
EBV-related Burkitt lymphoma
Tumor Growth Inhibition value (TGI) 
≈ 13.33
%
Raji cells
EBV-related Burkitt lymphoma
Tumor Growth Inhibition value (TGI) 
100
%
Raji cells
EBV-related Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
1
ng/mL
DoHH2 cells
Diffuse large B-cell lymphoma germinal center B-cell type
Half Maximal Inhibitory Concentration (IC50) 
4.7
ng/mL
Raji cells
EBV-related Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
7.6
ng/mL
SU-DHL-4 cells
Diffuse large B-cell lymphoma
Half Maximal Inhibitory Concentration (IC50) 
8.4
ng/mL
Ramos cells
Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
> 250
ng/mL
Ramos cells
Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
> 250
ng/mL
Jurkat cells
T acute lymphoblastic leukemia
Half Maximal Inhibitory Concentration (IC50) 
519
ng/mL
Granta-519 cells
Mantle cell lymphoma
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
1
ng/mL
SU-DHL-4 cells
Diffuse large B-cell lymphoma
Half Maximal Inhibitory Concentration (IC50) 
1.6
ng/mL
DoHH2 cells
Diffuse large B-cell lymphoma germinal center B-cell type
Half Maximal Inhibitory Concentration (IC50) 
4.7
ng/mL
Raji cells
EBV-related Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
7.6
ng/mL
Granta-519 cells
Mantle cell lymphoma
Half Maximal Inhibitory Concentration (IC50) 
8.4
ng/mL
Ramos cells
Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
> 2500
ng/mL
Jurkat cells
T acute lymphoblastic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 10 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 2.67% (Day 18) Positive CD22 expression (CD22+++/++)
Method Description
Free hB22.7 (0.6 mg/kg) plus free sap (0.36 mg/kg).
In Vivo Model Raji NhLcells xenograft model
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 13.33% (Day 18) Positive CD22 expression (CD22+++/++)
Method Description
HB22.7-sap (1 mg/kg).
In Vivo Model Raji NhLcells xenograft model
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% High CD22 expression (CD22+++)
Method Description
Nude mice were subcutaneously injected with 5 x 106 Raji cells. Twenty-four h later, designated as day 0, mice were randomly separated into three treatment groups (n = 810 per group) consisting of PBS, free HB22.7 (0.6 mg/kg) plus free SAP (0.36 mg/kg) and HB22.7-SAP (1 mg/kg).
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.00 ng/mL Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model Diffuse large B-cell lymphoma germinal center B-cell type DoHH2 cells CVCL_1179
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 4.70 ng/mL Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 7.60 ng/mL Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model Diffuse large B-cell lymphoma SU-DHL-4 cells CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 8.40 ng/mL Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 250.00 ng/mL Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 250.00 ng/mL Negative CD22 expression (CC22-)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model T acute lymphoblastic leukemia Jurkat cells CVCL_0065
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 519.00 ng/mL Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model Mantle cell lymphoma Granta-519 cells CVCL_1818
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.00 ng/mL Moderate CD22 expression (CD22++)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1 x104 cells/well in 90 uL media. HB22.7-SAP was serially diluted with media and 10 L of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model Diffuse large B-cell lymphoma SU-DHL-4 cells CVCL_0539
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.60 ng/mL Moderate CD22 expression (CD22++)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1 1 x104 cells/well in 90 uL media. HB22.7-SAP was serially diluted with media and 10 L of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model Diffuse large B-cell lymphoma germinal center B-cell type DoHH2 cells CVCL_1179
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 4.70 ng/mL High CD22 expression (CD22+++)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1x104 cells/well in 90 L media. HB22.7-SAP was serially diluted with media and 10 L of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 7.60 ng/mL Moderate CD22 expression (CD22++)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1x104 cells/well in 90 L media. HB22.7-SAP was serially diluted with media and 10 L of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model Mantle cell lymphoma Granta-519 cells CVCL_1818
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 8.40 ng/mL High CD22 expression (CD22+++)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1x104 cells/well in 90 L media. HB22.7-SAP was serially diluted with media and 10 L of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 2500.00 ng/mL Negative CD22 expression (CC22-)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1 x104 cells/well in 90 uL media. HB22.7-SAP was serially diluted with media and 10 uL of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model T acute lymphoblastic leukemia Jurkat cells CVCL_0065
References
Ref 1 Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. Oncoimmunology. 2012 Dec 1;1(9):1469-1475.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.